Abstract：
Non-tuberculous mycobacteria (NTM) infection is a major cause of morbidity in people with cystic fibrosis (pwCF) with rates of infection increasing worldwide. Accurate diagnosis and decisions surrounding best management remain challenging. Treatment guidelines have been developed to assist physicians in managing NTM in pwCF, but involve prolonged and complex mycobacterial regimens, often associated with significant toxicity. Fortunately, current management and outcomes of NTM in CF are likely to evolve due to improved understanding of disease acquisition, better diagnostics, emerging antimycobacterial therapies, and the widespread uptake of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
摘要：
非结核分枝杆菌（NTM）感染是囊性纤维化（pwCF）患者发病的主要原因，全球感染率不断增加。围绕最佳管理的准确诊断和决策仍然具有挑战性。已经制定了治疗指南，以帮助医生在pwCF中管理NTM，但涉及长期复杂的分枝杆菌疗法，通常与显著的毒性有关。幸运的是,CF中NTM的当前管理和结果可能会由于对疾病获取的理解的提高而演变，更好的诊断，新兴的抗分枝杆菌疗法，以及囊性纤维化跨膜传导调节因子（CFTR）调节剂疗法的广泛摄取。
